Saxenda (liraglutide 3.0mg) is FDA-approved for weight management in adolescents aged 12-17 with obesity
Dejgaard TF, Frandsen CS, Hansen TS et al (2016) Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
Bonello, who herself has taken compounded GLP-1 products, says for many patients shes spoken to, the impact of these medications is not just about the weight itself
Other downregulated processes included those involved in the pathogenesis of a variety of cardiomyopathic states, including cardiac muscle contraction, hypertrophic cardiomyopathy, dilated cardiomyopathy, and diabetic cardiomyopathy